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Abstract 
 
     Introduction: To reduce denitrogenation time to prevent decompression sickness to support 
frequent extravehicular activities on the Moon, and to limit the risk of fire, a hypobaric (PB = 414 
mmHg) and mildly hypoxic (ppO2 = 132 mmHg, 32% O2 - 68% N2) living environment is being 
considered during lunar missions for the Crew Exploration Vehicle (CEV) and Lunar Surface 
Access Module (LSAM). If the vehicular ppO2 is acutely changed from 145-178 mmHg at 
standard vehicular operating pressure to less than 125 mmHg at desired lunar surface outpost 
operating pressures, there is the possibility that some crewmembers may develop symptoms of 
Acute Mountain Sickness (AMS). The signs and symptoms of AMS (headache plus nausea, 
dizziness, fatigue, or sleeplessness), could impact crew health and performance on lunar surface 
missions. Methods:  An exhaustive literature review on the topic of the physiological effects of 
reduced ppO2 and absolute pressure as may contribute to the development of hypoxia and altitude 
symptoms or AMS. The results of the nine most rigorous studies were collated, analyzed and 
contents on the physiological concerns associated with hypobaric operations, AMS and hypoxia 
https://ntrs.nasa.gov/search.jsp?R=20070032076 2019-08-30T01:42:00+00:00Z
symptoms summarized. Results:  Although space vehicles have operated in hypobaric conditions 
previously, they have not operated in a mildly hypoxic ppO2. There is evidence for an absolute 
pressure effect per se on AMS, such that the higher the altitude for a given hypoxic alveolar O2 
partial pressure (PAO2), the greater the likelihood of an AMS response.  About 25% of adults are 
likely to experience mild AMS near 2,000 m (xxx mmHg) altitude following a rapid ascent from 
sea level while breathing air (6,500 feet, acute PAO2 = 75 mmHg).  The operational experience 
with the Shuttle staged denitrogenation protocol at 528 mmHg (3,048 m) while breathing 26.5% 
O2 (acute PAO2 = 85 mmHg) in astronauts adapting to microgravity suggests a similar likely 
experience in the proposed CEV environment.  Conclusions:  We feel that the slightly elevated 
risk of AMS with the recommended exploration atmospheric parameters is offset by the DCS risk 
reduction and improved operational efficiency offered by the hypobaric lunar surface vehicular 
pressure. We believe the risk of mild AMS is greater given a PAO2 of 77 mmHg at 4,876 m 
altitude while breathing 32% O2 than at 1,828 m altitude while breathing 21% O2.  Only 
susceptible astronauts would develop mild and transient AMS with prolonged exposure to 414 
mmHg (4,876 m) while breathing 32% O2 (acute PAO2 = 77 mmHg).  So the following may be 
employed for operational risk reduction:  1) develop procedures to increase PB as needed in the 
CEV, and use a gradual or staged reduction in cabin pressure during lunar outbound; 2) train 
crews for symptoms of hypoxia, to allow early recognition and consider pre-adaptation of crews 
to a hypoxic environment prior to launch, 3) consider prophylactic acetazolamide for acute 
pressure changes and be prepared to treat any AMS associated symptoms early with both 
carbonic anhydrase inhibitors and supplemental oxygen. 
  
 
 
1. Introduction 
  
     Future long duration spacecraft, spacesuits, lunar and Mars habitats are being 
developed at NASA centers, under the leadership of Johnson Space Center in support of 
the Vision for Space Exploration, also known as Constellation35. Several atmospheric 
design points for the Constellation missions have been developed by the Environmental 
Atmosphere Working Group (EAWG) ranging from normoxic to moderately hypoxic and 
normobaric to hypobaric6. These environments were analyzed to achieve a balance 
among the risk of decompression sickness, the overhead required to perform an 
exploration extravehicular activity (EVA), short and long term human performance at 
less than normoxic levels of partial pressure of oxygen (ppO2), and the fire hazard. To 
limit the risk of fire, reduce the risk of decompression sickness and reduce the prebreathe 
time to support frequent extravehicular activities (EVAs) on the Moon, and later Mars, a 
hypobaric and mildly hypoxic living environment was proposed for the Crew Exploration 
Vehicle (CEV), the Lunar Surface Access Module (LSAM), and long-term surface 
habitats (Table 1).   
 
Table 1. Summary of Recommendations for Constellation Mission Systems  
 
 
Vehicle 
Nominal 
Total Pressure 
(psia +/- 0.2psia)4
Nominal 
Oxygen  
Partial 
Pressure  
(mmHg) 4
Nominal 
Oxygen 
Concentration  
(% +/- 2.0 
percentage 
points)4
 
Equivalent 
Air 
Altitude 
 
feet 
 
Range of 
Total 
Pressure 
Capability 
(psia) 1
 
 
Tissue Ratio (R) 
After 60 Minutes 
Prebreathing3
CEV to ISS             14.7 10.25
160 ( 0 ft ) 
140 (3500 ft) 
21 
26.5 
0 
4,000 0-14.9 
CEV In-Space 
Suit 4.3 222 100 
 
4.0-4.6 1.55 from 10.2 psia CEV to 4.3 psia suit 
  
Lunar and 
Mars CEV 
14.7 
10.2 
160 ( 0 ft ) 
140 (3500 ft) 
21 
26.5 
        0 
     4,000 0-14.9 
Lunar and 
Mars Landers 
10.2 
8.0 
140 (3500 ft) 
132 (5000 ft) 
26.5 
32 
4,000 
6,000 0-14.9 
Lunar and 
Mars Surface 
Suits 
4.3 
6.0 
222 
310 
100 
100 
 
3.5-8.0 2
1.13 from 8.0 psia 
Landers to 4.3 psia 
suit;  
 
1.07 from 7.6 psia 
Surface Habitats to 
4.3 psia suit 
Lunar and 
Mars Surface 
Habitats 
8.0 
7.6 
132 (5000 ft) 
126 (6500 ft) 
32 
32 
6,000 
7,500 0-14.9 
Mars Transit  14.7 10.2 
160 ( 0 ft ) 
140 (3500 ft)  
21 
26.5 
0 
4,000 0-14.9 
 
Note 1:  Range of total pressure capability covers Earth launch, Earth entry, and contingencies.     
Note 2:  Surface suit 3.5 psia capability for suit emergency operations, 8.0 psia for DCS treatment. 
Note 3: 60 minute in-suit prebreathe is defined as the time in the suit after purge and leak check until   
             absolute pressure on the body reaches 4.3 psia after a nominal depressurization. 
Note 4:  All nominal values are centers of control boxes assumed +/-0.2 psia total pressure, +/-2 percentage  
             points oxygen. 
Note 5: 10.2 psia recommendation is based on Shuttle experience, for CEV contingency EVA preparation. 
 
     The hypobaric and reduced oxygen environment is being recommended by the EAWG as an  
integrated solution to safety, engineering, operational, and medical concerns that have as their 
goal routine and safe exploration of the Lunar or Martian surface. Indeed, the Constellation 
program goals and proposed mission architecture emphasize EVA with exploration of planetary 
surfaces as the central driving operation. We present an analysis of risk of crew symptoms 
associated with proposed Constellation vehicle O2 partial pressure (ppO2). Extended exposures 
to even mild hypoxic stress can lead some to signs and symptoms of Acute Mountain Sickness 
(AMS). This is a concern in any aerospace application where mild hypoxia is deemed an 
acceptable trade. The goal of any trade process is an integrated product, and each stakeholder 
accepts a less than ideal outcome. Each stakeholder then develops a strategy to minimize the 
impacts of their less than ideal outcome. Our goal is to understand the risk of AMS, and then 
develop strategies to minimize any perceived risk. 
  
 1.1 Assumptions 
     Future vehicles for exploration missions will have less than atmospheric PB, with a 
ppO2 less than a sea level equivalent of 160 mmHg (3.07 psia). An efficient exploration 
program requires that EVA be efficient.  The time to prepare for EVA should be minimal, 
and the suit pressure should be low to accommodate EVA tasks without undue fatigue, 
physical discomfort, or even suit-related trauma.  Currently, a long prebreathe time is 
used prior to EVA from the Shuttle and the International Space Station to prevent DCS 
and significant venous gas emboli (VGE) insult of the lungs at low suit pressure.  To 
shorten this prebreathe time, the habitat atmosphere should not have a high partial 
pressure of nitrogen (ppN2).  One practical approach to reduce the ppN2 is to increase the 
ppO2 while also reducing PB.  A balance must be achieved between the increased risk of 
fire at high O2 concentration and the decreased risk of DCS as ppN2 in the habitat is 
reduced.  The concentration of O2 and therefore the risk of fire for a given PB can be 
reduced if mild hypoxia is considered.  So for good reasons, a modest hypobaric and 
hypoxic (HH) environment (see Table 2) with crews adapted to microgravity (μG) is one 
option for future Moon and Mars exploration.   
  
 Table 2.  Range of Atmospheric Conditions in Proposed Living Environments. 
    
Environment PB 
psia   mmHg 
FIO2 
(%) 
PIO2 
mmHg 
PAO2* 
mmHg 
Actual Altitude 
m           feet 
Equivalent Air 
Altitude 
m            feet 
CEV + LSAM 
               
normal 8.0       414 32.0 117 77 4,877    16,000 1,829      6,000 
best case 8.2       424 34.0 128 86 4,816    15,800 1,158      3,800 
worse case 7.8       403 30.0 107 68 5,029    16,500 2,438      8,000 
Habitat 
      
normal 7.6       393 32.0 111 71 5,182    17,000 2,286      7,500 
best case 7.8       403 34.0 121 80 5,029    16,500 1,524      5,000 
worse case 7.4       383 30.0 101 63 5,364    17,600 2,895      9,500 
 
PIO2 is inspired O2 partial pressure, computed as (PB mmHg – 47) * FIO2 (as decimal percent). 
* computed value is for an acute altitude exposure with a “typical” adult exhibiting a “typical” response to 
mild hypoxia.  The exact value for PAO2 seen in the table would not likely be measured in a small sample 
of adults exposed to the conditions listed in the table.  
When breathing an atmosphere that does not contain 20.9% O2, it is helpful to determine the Equivalent 
Air Altitude by using the alveolar oxygen equation since most experience with hypoxia is with ascent to 
altitude while breathing air.   
 
     
1.2 Unknowns 
     The nominal Equivalent Air Altitudes of 6,000 and 7,500 feet do not reflect the 
complete hypoxic stress since current literature indicates that AMS is a function of both 
the alveolar oxygen partial pressure (PAO2) and the total ambient pressure (PB).  It is 
unclear how to combine the two components of hypoxic stress to understand the true risk 
of AMS.  Superimposed on physiological adjustments to living in a hypobaric hypoxia 
(HH) environment are physiological adjustments associated with adaptation to 
microgravity (μG).  There is a concern that the combination of these stresses will degrade 
the health and performance of astronauts who must maintain a high level of proficiency 
to accomplish mission goals.   
  
  Superimposed on physiological adjustments to living in a HH environment are 
physiological adjustments associated with adaptation to μG, particularly a significant 
increase in blood viscosity.  There is some uncertainty on the full impact that the 
combination of these stresses will have on the health and performance of astronauts who 
must maintain a high level of proficiency to accomplish exploration mission goals.  
Therefore, it is prudent to recommend an operational ppO2 that does not fall into a 
physiological area of uncertainty, and to have a risk mitigation strategy for cases when 
operations push towards the limits of the known safe operational range. 
 
2. Methods 
 
     An extensive review of the current database of altitude physiology, alterations in physiology 
occurring with exposure to microgravity, characteristics of materials exposed to various 
environmental atmosphere conditions, and prior spaceflight mission technical reports was 
conducted. This report provides responses to the three important questions related to AMS:.   
 
1.  Is there an absolute PB effect per se on the risk of AMS induced by HH?   
2.  Is there an increased risk of AMS when HH is combined with adaptations to μG? 
3.  Is there an amplified increase in blood viscosity when HH is combined with adaptation to 
μG? 
The following sections review current literature about AMS and pertinent literature about 
adaptive changes in simulated or actual μG exposures, with and without additional hypoxic 
stress.  Since significant uncertainties do exist to resolve the above questions, a risk mitigation 
  
plan must be developed to minimize the impact of mild hypoxia combined with adaptation to 
μG. 
 
3. Results 
 
3.1 The Risk of AMS 
     Roach [3] says that quick ascent to altitudes over 2,590 m (8,500 ft) often results in symptoms 
of AMS.  Nearly 25% of people are affected even at 1,981 m (6,500 ft) [3-5].  Others [6] find no 
significant symptoms below 3,048 m (10,000 ft).  Many factors modify the risk of AMS between 
1,981 and 3,048 m, particularly the rate of ascent to altitude, activity level at altitude, and 
individual susceptibility.  One reality about NASA space vehicles is that depressurization to a 
final hypobaric PB can be on the order of minutes and not hours or days, although a more 
gradual pre-down approach could be instituted.        
     AMS is a constellation of signs and symptoms including headache, nausea, dizziness, fatigue, 
and sleeplessness that develops over a 6 – 24 hour stay in a hypoxic environment, usually from 
rapid ascent to altitude while breathing ambient air [7].  The headache, for example, is usually 
throbbing, bitemporal or occipital, typically worse during the night and on awakening, and made 
worse by Valsalva’s maneuver, and combined with nausea can be likened to an alcohol-induced 
hangover.  Additional clinical findings that confirm a diagnosis include changes in mental status, 
ataxia, peripheral edema, or changes in performance.  A change in performance means that any 
of the above symptoms or clinical findings have caused a reduction in normal activities.    
 
3.1.1 Data for Pressure Effect per se on AMS 
  
     The Alveolar Oxygen Equation (AOE) was applied to several tests referenced in this report 
[8].  It is the key physiological variable to associate changes in the breathing environment to 
changes in other physiological systems.  The acute respiratory changes, hyperventilation with the 
resulting increase in respiratory exchange ratio (RQ), caused by hypoxic stress induced from an 
ascent to altitude while breathing air or from breathing a hypoxic atmosphere while at sea level 
make it difficult to understand the resulting PAO2 without the aid of this equation.  Also, the 
disproportionate contribution of water vapor toward decreasing PAO2 as PB decreases is 
managed in the AOE. 
 
PAO2 = FIO2 * (PB - 47) - PACO2 * [FIO2 + ((1 -  FIO2) / RQ)] 
 
where PAO2 is alveolar O2 partial pressure (mmHg),  FIO2 is inspired O2 fraction (decimal 
percent), PB is ambient pressure (mmHg), 47 is the vapor pressure of water at 37 c (mmHg), 
PACO2 is alveolar CO2 partial pressure (mmHg), and RQ is the respiratory exchange ratio 
(unitless), equal to 1.0 when breathing 100% O2.   
     Our goal was to evaluate results from tests where computed hypoxic PAO2 were very similar 
between two tests but with different PBs.  It is possible to achieve the same computed PAO2 
under four different experimental conditions where PAO2 and ambient PB are manipulated.  A 2 
X 2 matrix of PAO2 and PB combinations is possible:   
 
NN – normobaric normoxia, where PB = 760 mmHg and PAO2 = 103 mmHg (sea level control), 
NH – normobaric hypoxia, where PB = 760 mmHg and PAO2 < 103 mmHg (FIO2 <21%),  
  
HN – hypobaric normoxia, where PB < 760 mmHg and PAO2 = 103 mmHg (FIO2 >21%), and 
HH – hypobaric hypoxia, where PB < 760 mmHg and PAO2 < 103 mmHg (FIO2 > 21%). 
 
    The assumptions are that identical computed hypoxic PAO2 between two different tests 
should result in equivalent hypoxic responses, and that the computed PAO2 is accurate.  So if an 
equivalent hypoxic response is not observed, then it follows that it must be caused by something 
other than a difference in PAO2.  But PAO2 is extremely dynamic, and then there is individual 
variability in how the central nervous system in conjunction with the respiratory system reacts to 
mild hypoxia, both during an acute and chronic exposure.  So the caveat is to consider computed 
PAO2 as a “best estimate”, not as an absolute.  Always consider the possibility that there is a true 
difference in PAO2 in two experiments that purport to be equivalent hypoxic exposures when 
identical computed PAO2 is offered as evidence of their equivalency. 
     The complex cardiovascular-pulmonary-cerebral-renal-hematological-endocrine response to a 
hypoxic environment is assumed to be identical whether you are in a hypoxic environment while 
at altitude in an otherwise comfortable altitude chamber or if you breathe an equivalent hypoxic 
mixture in the same altitude chamber at sea level PB.  This assumption has recently been called 
into question.  The concept of equivalent air altitude exposure is that there is no difference in 
hypoxic response at any altitude as long as the same PAO2 is achieved at two different altitudes 
by breathing the proper supplemental O2.  The routinely applied notion of an “equivalent air 
altitude exposure” is invalid for higher altitude if it is true that there is an absolute PB effect on 
the risk of AMS, certainly if two different altitudes are supposedly equivalently hypoxic.     
  
     There are hundreds of reports about HH and hundreds of reports about NH, but unfortunately 
there are fewer than nine reports where the combination of HH and NH were tested together or 
HH, NH, and HN were tested together to specifically look for a PB effect per se on AMS.  The 
sum total are listed here in ascending chronological order: Tucker [9-10], Grover [11], Levine 
[12], Roach [13-14], Loeppky [15-16], Savourey [17], and Leoppky [18].   
     Two of these studies [10] [14] speak directly to the AMS scores, while the others document 
physiological measurements that show a difference between HH and NH exposures even though 
computed PAO2 between the test are similar.  Tucker [10] takes men already living at 1,524 m 
(5,000 ft) altitude in Colorado (PAO2 = 77 mmHg from AOE) to either 4,572 m (15,000 ft) 
while breathing air in an altitude chamber or while at site pressure breathing a hypoxic mixture 
(about 14% O2 and 86% N2) such that computed PAO2 for the HH and NH exposures are about 
45 mmHg.  Even though the arterial blood O2 saturation was about 81% in both tests, the mean 
AMS score (not based on Lake Louise system) for the NH exposure was 3.2 compared to 6.7 for 
the HH exposure.  Roach [14] and Loeppky [15] [18] confirm this basic observation with men 
also living at 1,524 m altitude in New Mexico.  Again, an ascent to 4,572 m while breathing air 
in an altitude chamber was compared to breathing a hypoxic mixture at site pressure.  The AMS 
scores (based on Lake Louise system) increased from 2.0 to 3.7 in Roaches’ work, while 
Loeppky confirms that modest hypoventilation [16] combined with mild edema [18] under HH 
relative to NH conditions likely explains the differences in AMS scores.   
     So there appears to be a PB effect per se at work on physiological responses and signs and 
symptoms (onset time, incidence, and severity) of AMS based on a review of literature from 
1980 to the present [19].  This statement is “conditional” on the fact that hypoxia is present.  The 
  
current research says that you should not assume all AMS outcomes would be equivalent given 
only equivalent hypoxic PAO2.  This has led to the clinical observation that the most effective 
treatment for AMS is the application of increased PB to achieve a particular treatment PAO2 
instead of increasing the percentage of O2 at the current lower PB to achieve the same treatment 
PAO2 [20].  
 
3.1.2 Body Fluid Balance and RBC Changes in Microgravity 
     The adaptive response to μG exposure is a reduction in total body fluid [21], followed by a 
reduction in red blood cell (RBC) mass over a longer period, but with little change in hematocrit 
(HCT) in the absence of hypoxic stress [22].  Prior to the reduction in body fluid there is cephalic 
shift of fluid leading to a loss of leg fluid volume, with excess fluid distributed into the face and 
chest.  Pulmonary capillary blood volume increases by about 25%.  The initial fluid shift 
increases stroke volume.  Stretch receptors in the arterial circulation and in the heart sense 
changes in the central blood volume, so water immersion, supine or head-down bedrest and 
exposure to μG are all sensed as an increase in central blood volume.  In response, there is a 
decreased renal sympathetic drive, a decrease in renin activity from the kidneys leading to 
decreased ALD secretion [23].  Plasma volume drops rapidly to about 17% [23].  Part of this 
reduction is due to loss of fluid to the extravascular space.  There is a transient increase in HCT 
which would reduce erythropoietin (EP) secretion, which does decrease in space [24].  The net 
result in a normoxic environment is a reduction in RBC mass.  In a significant hypoxic 
environment, EP production would be stimulated.  Erythropoietin secretion requires altitude of 
about 2,500 m (8,200 ft) or greater, and exposures longer than six hours [25].   
  
     A dysfunction in the body’s handling of water is proposed as one factor in the development of 
AMS.  Individuals who show diuresis upon arrival at high altitude appear to function better than 
those who exhibit an antidiuresis response.  The most affected subjects show a marked reduction 
in urine flow associated with elevated levels of ADH [18] [26].  It is not clear whether the 
increase in ADH is a response to net fluid loss into the extravascular space or the cause initiated 
by an unknown mechanism triggered by HH.  Fluid shifts from the intravascular space to the 
extravascular space leads to edema, with significant problems if the result is cerebral edema or 
pulmonary edema.  As mentioned earlier, there is a hypoxic component as well as a hypobaric 
component to AMS, and now fluid volume changes and redistribution associated with μG 
adaptation may contribute to AMS.   
     A concern with any decrease in plasma volume, with or without an accompanying edema, is 
that the rheological properties of the blood will change ultimately leading to impaired 
cardiopulmonary performance through a change in viscosity.  Viscosity is a property of fluid 
related to the internal friction of adjacent fluid layers sliding past one another as well as the 
friction generated between the fluid and the wall of the vessel.  This internal friction contributes 
to the resistance to flow.  The viscosity of plasma is about 1.8-times the viscosity of water 
(termed relative viscosity) at 37°C and is related to the protein composition of the plasma.  
Whole blood has a relative viscosity of 3-4 depending upon HCT, temperature, and flow rate.  
As HCT changes in response to μG adaptation and HH, significant changes in blood viscosity 
become a concern.  
     It is known that deconditioning and fluid redistribution occurs during extended bedrest, 
bedrest with head down tilt, and exposure to μG.  There is a decrease in total blood volume 
through a combined loss in plasma volume and RBC mass [27] [23] [28] [22].  Hematocrit 
  
transiently changes during this period of adaptation, but returns to near-baseline values over 
several weeks in a NN environment.  Exposure to significant HH leads to an increase in RBC 
mass with an expected increase in HCT [22] [29] and blood viscosity [30] [31].  An increase in 
HCT above 55% increases blood viscosity where the decrease in cardiac output more than offsets 
the gain in O2 capacity of the blood.  This combination leads to a decrease in O2 transport [29] 
[32]. 
 
3.1.3 Potential Integrated Response  
     There are hundreds of reports about HH without μG simulation, and hundreds of reports about 
μG simulation under NN conditions.  But the unfortunate reality is that there are fewer than 10 
reports in the United States where the combination of HH and adaptation to μG were tested 
together.  And in some of these reports the degree of μG adaptation was limited to just hours on a 
tilt table, so have limited application here.  The sum total are listed here in ascending 
chronological order:  Stevens [33], Lynch [34], Waligora [35], Fulco [36], Loeppky [37-39], and 
Whitson [40]. 
     The increase in HCT from about 42 to 45% during 10 days of 6-degree head down bedrest 
from Martin [30] was similar to the increase from 43 to 46% for 6-degree head down bedrest 
after 28 hours reported by Waligora [35] with subjects exposed to 2,438 m (8,000 ft) altitude for 
eight hours, and the increase from 42 to 48% for supine subjects after 114 hours at 4,300 m 
(14,000 ft) reported by Fulco [36].  The results from Fulco [36] are similar to Stevens [33] and 
Loeppky [38-39].  They show increases from 43.6% to 50.9% and from 47% to 52% when head 
down bedrest over many days was combined with HH from ascent to between 3,048 and 3,657 m 
(10,000 and 12,000 ft).  It is important to note that the baseline data from Loeppky with 47% 
  
HCT is from subjects pre-adapted to living at about 1,524 m, but the difference of 5% from the 
combined head down bedrest and HH is comparable to the 6% difference from Stevens [33] and 
the 6% difference from Fulco [36].  There is no obvious negative synergistic interaction between 
HH exposure with μG adaptation that appears across the experimental conditions in six 
applicable reports.   
 
3.2 Physiological concerns 
 
     The proposed spacecraft and habitat environmental atmosphere take into the account 
the following along with the inherent risk of developing AMS: 
 
3.2.1 Crewmember Physiology 
     Under standard atmospheric conditions of 14.7 psia pressure and ppO2 3.0 psia (159 
mmHg), approximately 98% of the hemoglobin will be saturated with oxygen during 
passage through pulmonary capillaries. This is reflected in the oxygen-hemoglobin 
dissociation curve when the PAO2 is 100 mmHg. The PAO2 takes into consideration the 
dilutional effects of water vapor and carbon dioxide at the level of the alveoli, hence the 
lower value.  
     Technically, as the PAO2 falls below 100 mmHg (1.93 psia) the hemoglobin begins to 
desaturate, resulting in a relative “hypoxic” zone. Clinically, symptoms of hypoxia are 
not observed in healthy individuals until the PAO2 enters the steep portion of the curve, 
generally below 60 mmHg (1.16 psia) corresponding to a hemoglobin saturation of less 
than 90%. This corresponds to an equivalent altitude in non-acclimatized individuals of 
greater than 10,000 ft above sea level11,17  
  
     Interestingly, the amount of alveolar carbon dioxide, PACO2, and water vapor pressure 
change little at this altitude, adding to the dilutional effects. Reduced atmospheric 
pressure with concomitant reduction in PAO2 below 60 mmHg has several acute effects 
including decreased mental proficiency, visual acuity, muscle fatigue, nausea, headache, 
and impaired discrete motor movements, 11,15,17  similar to what has been described as 
AMS. 
3.2.2 The Risk of AMS on Constellation Vehicles 
     There was not an abundance of data or even a small amount of data specific to our 
environmental conditions.  There were only four reports about a PB effect per se on the risk of 
AMS induced by HH and six reports on the combined effects of HH and simulated μG 
adaptation that have some application here.  So all conclusions made here are based on 
extrapolation or interpolation from limited information.  In this regard, it was verified with 
confidence that there is an absence of data specific to the exploration risk scenario.  Even a small 
amount of best data are not directly applicable.  Data from Roach, Loeppky, and Tucker are 
specific to subjects that lived for years at about 1,524 m altitude in New Mexico and Colorado.  
Clearly changes associated with these tests are less than expected if applied to subjects who 
ascend from sea level to the test altitude.  In addition to the lack of applicable data, there is also a 
clear lack of data for women exposed to HH, to simulated μG adaptation, and the combination of 
HH and simulated μG adaptation.        
     There is one example where mild hypoxia is produced through the combination of enriched 
O2 (>21%) under hypobaric conditions (PB < 760 mmHg) and has been used with hundreds of 
subjects over several days, with and without adaptation to μG.  These data are from the ground 
  
testing and good operation experience of the Shuttle staged denitrogenation protocol.  The data 
are marginally applicable here since good operational experience is not equivalent to quality 
research data, and the Shuttle conditions are not identical to those currently planned for the CEV, 
and beyond.  Subjects in an altitude chamber and later astronauts on the Shuttle spent hours to 
days at 10.2 psia (10,000 ft) breathing 26.5% O2 as a means to partially denitrogenate body 
tissues prior to depressurization to 4.3 psia with 100% O2.  The PAO2 is computed at 85 mmHg 
during the staged protocol, equivalent to breathing air at 1,219 m (4,000 ft) if we discount the 
current discussion about the validity of applying the idea of “equivalent air altitude exposure”.  
The point is that the good testing and operational experience with this protocol suggests that 
there is no significant negative synergy between very mild HH and μG.  But it is an extrapolation 
to conclude anything about the worse case PAO2 of 68 mmHg at 5,029 m (16,500 ft) in 
astronauts adapting to μG in the CEV based on the literature reviewed for this report.  
     Although initial signs and symptoms of AMS in susceptible subjects are expected after 
prolonged exposure to between 1,981 m (6,500 ft at PAO2 = 75 mmHg) and 2,590 m (8,500 ft at 
PAO2 = 67 mmHg), it is likely that these would be self-limiting once acclimatization proceeds 
[3].  Roach [14] and Tucker [10] have the best data from which to conclude that AMS is very 
likely for some people exposed to 4,572 m (15,000 ft) with a PAO2 of about 45 mmHg in 
subjects pre-adapted to living at 1,524 m.  Therefore, at 8.0 psia (4,876 m or 16,000 ft) with a 
nominal PAO2 = 77 mmHg in astronauts not pre-adapted to living at 1,524 m altitude it is likely 
that susceptible astronauts simultaneously undergoing adaptation to μG [38-39] will experience 
signs and symptoms of AMS.  It is unlikely that a clinically significant increase in HCT will 
occur.  A transient increase to a mean HCT of about 50%, possibly as high as 55% in a particular 
  
crewperson, would be predicted based on the data [33] [38-39] for the combined effects of HH 
and adaptation to μG as envisioned for the CEV program.  However, typical μG adapted 
spaceflight HCT values are in the low normal range, from 36-40% depending on gender. 
     There are several examples where the physiological changes initiated by HH and adaptation 
to μG are in opposite directions.  Therefore, the net effect is a blunted response when both 
conditions occur simultaneously.  For example, HH increases sympathetic drive through the 
release of catecholamines [36] [41] [42-43] while supine or head down bedrest reduces 
sympathetic drive (Volicer 1976)need Ref.  HH increases RBC mass that is opposite the decrease 
seen in extended bedrest and exposure to μG [27].  Some even propose that the compensations 
for HH provide a beneficial therapy for cardiovascular deconditioning associated with extended 
bedrest [45-46] [34].  One example for a negative synergy is a possible enhanced reduction of 
the ventilatory response to hypoxia.  The classic response to hypoxia is to increase ventilation, 
but the increase is slightly less if the hypoxia is caused by a hypobaric exposure compared to the 
same hypoxia caused in a normobaric condition [17].  Prisk [47] shows a reduction in ventilatory 
response to hypoxia in normocapnic subjects during supine and μG exposure compared to 
standing subjects.  The notion is that increase in blood pressure due to body position modifies the 
ventilatory response to hypoxic challenge.  The two studies are not directly comparable, but this 
may be a case where HH and adaptation to μG lead to a greater reduction in ventilatory response 
to hypoxia that either in isolation would cause.  This is not an ideal situation if the goal is to 
avoid AMS associated with a suppressed ventilatory response to hypoxia.  Rahn [48] even shows 
that hyperventilation on standing after being supine increases PAO2 as PACO2 drops from about 
42 mmHg to 37 mmHg in response to the hyperventilation.  So body position modifies PAO2, 
and it is unclear how μG influences PAO2 given that body position is irrelevant.  Finally, it can 
  
be argued from the work of Loeppky [38-39] that HH and μG simulation produced changes that 
are additive.  He shows an additional loss of plasma volume, with an additional increase in 
hemoglobin and HCT given a PAO2 = 59 mmHg at 3,361 m (10,700 ft) altitude in subjects 
exposed eight days to 5-degree head down bedrest compared to the loss of plasma volume and 
increase in hemoglobin and HCT in subjects just exposed to 3,361 m altitude.  On balance, there 
is no definitive evidence for an exaggerated (negative synergistic) response to the combination of 
HH and adaptation to μG.  On the contrary, the limited evidence suggests that one stressor tends 
to counteract the other. 
      In an attempt to understand the possible physiological interaction of hypoxia and 
microgravity, researchers at NASA Glenn Research Center analyzed existing data 
assuming a long duration mission in mildly hypoxic conditions, equivalent to 5,000-8,000 
ft.15 Observations made from the data (Table 3) reveal that relatively little change occurs 
in blood viscosity between 0-5,000 ft. However, the blood viscosity increases between 
15-50% when crew members have been exposed to microgravity at altitudes of 8,000 ft. 
The authors concluded that the combination of hemoconcentration from PV loss and 
increased RBV result in increased blood viscosity. The clinical concern is that increased 
blood viscosity, in the setting of reduced circulation in the lower extremities and overall 
reduced venous system tone, may increase the risk of cardiovascular events, such as 
thrombi formation.15,27,29 
 
Table 3. Estimated changes in blood volume components and hematocrit based on 
the case of long duration exposure (chronic conditions) to both microgravity and 
mildly hypoxic atmospheric conditions. (Courtesy of DW Griffin, JG Meyers. 
Biomedical Effects of Proposed CEV Atmospheres. NASA Glenn Research Center, 
2005) 
 
  
Atm 
Equivalent 
Altitude 
(ft) 
 
Change 
in PV 
(ml) 
 
Total 
PV 
(ml) 
 
Change 
in RBV 
(ml) 
 
Total 
RBV 
(ml) 
 
TBV 
(ml) 
 
Hematocrit 
(%) 
 
*Relative 
Viscosity
0-5000 0 2764 0 1824 4588 40 4 
6000 -91 2673 170 1994 4667 43 4.6 
7000 -183 2581 340 2164 4745 46 5.3 
8000 -274 2490 509 2333 4823 48 6 
*Relative Viscosity is defined as the blood’s viscosity relative to that of water at 37oC.Note that an average 
body mass of 68.2 kg was assumed to conform to Skylab 4 astronaut conditions on return (R+0).  
 
 
     However, there have been no observed or reported episodes of thrombus or embolus in either 
animals or humans during short or long duration spaceflight, so this concern may be only 
theoretical. This observation is consistent with periodic health assessment information from ISS: 
after the initial period of hemoconcentration that occurs during early microgravity exposure 
(adapting to fluid shifts and subsequent diuresis), the hematocrit normalizes (ISS crew at ppO2 of 
145-170 mmHg) and stays in the low normal range throughout the remainder of the mission. One 
means to reduce the perceived risk associated with this uncertainty is to operate the vehicle 
atmosphere within our existing microgravity experience base during the microgravity transit 
phase, then transition toward the lower habitat pressures and ppO2 levels gradually. Gravity in 
lunar and Mars missions and its effects on pulmonary and cardiovascular physiology is another 
consideration, although it is not likely to have physiological significance.   
     Individual susceptibility to μG adaptation in a HH environment will likely play a role in 
mission success (including an absence of medical problems) in these short-term missions with 
high EVA-rate scenarios.  Some peak performance degradation could be expected in 
crewmembers, if ppO2 is reduced acutely to less than 145 mmHg (2.8 psia), until compensation 
occurs.  The magnitude of the performance affect will depend on the ppO2, the metabolic 
demands of the task, and individual genetic factors.  Current threshold for mandatory 
  
supplemental O2 during spaceflight operations is 111 mmHg (approx. 2.2 psia)
Ref Vol B ISS FR’s.  
For lunar outpost missions (approximately 6 months surface stays), full acclimatization to 
reduced ppO2 can be expected after 30-45 days, allowing crews to function at high performance 
levels in the face of reduced O2 tension. In summary, the lunar missions will serve to build our 
experience base prior to conducting the longer duration Mars missions. 
 
3.3 Launch to En Route Cabin Pressure and Oxygen Concentration Changes 
 
     The proposed atmospheric transition after launch is displayed graphically in figure 1. 
The transition from sea level atmospheric pressure and oxygen concentration (14.7 psia 
and 21% O2) to an en route cabin pressure and oxygen concentration range of 10.2 psia 
and 26.5% O2 (3,500 ft) to 8.0 psia and 32% O2 (5,000 ft) would likely use procedures 
similar to those currently practiced on shuttle and ISS missions. The launch cabin 
pressure would be staged down initially to ~10.2 psia and the O2 enriched to ~26.5% 
consistent with existing shuttle and station flight rules.23 If it was desired to reduce the 
ppO2 to lower levels to provide for a slow acclimatization to the Lander and Habitat ppO2 
(~ 2.56 psi), then it should be relatively straight forward to breath down the oxygen 
gradually over time consistent with some TBD acclimatization protocol. During the 
lander/CEV docked operations the cabin pressure and FiO2 would be consistent with the 
CEV limitations on O2 concentration (< 30%). Once the crew had transferred into the 
Lander and undocked from the CEV, the cabin pressure could be further reduced and the 
O2 concentration would be elevated to 32%. There is no physiological time constraints to 
when this depress could occur. Consequently, there is little risk of DCS associated with 
this pressure transition as it is below the threshold for tissue supersaturation. 
  
 Figure 1. Concept for Lunar-Mars CEV Atmosphere Transition on Earth Ascent. 
(Adapted from Henninger D, Campbell PD. Briefing to SLSD on EAWG 
Recommendations, January, 2006.NASA/JSC Bioastronautics Exploration Research 
and Technology Office) 
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3.4 Risk of Decompression Sickness 
     Decompression sickness is a potentially debilitating and life-threatening condition that 
occurs when inert gas, typically N2, evolves out of the blood and body tissues. The 
evolved gas can compress nocioceptive tissues causing pain (“the bends”), or interrupt 
venous or arterial blood flow, or other vascular and neurological disorders.3,11 An 
individual is at risk of developing DCS whenever exposed to an ambient pressure lower 
than the tissue nitrogen tension. In order to estimate the severity of DCS, the tissue ratio, 
  
or R-value, R, was developed. The R-value is defined as the ratio of the tissue nitrogen 
tension in 360 minute half-time tissue before depressurization to the ambient pressure 
after depressurization: 
  R =  PN2-Tissue 
    PSuit 
 
     In general, the higher the R-value above 1.0, the greater the likelihood of DCS.4,21 
However, a number of other variables influence the likelihood of developing DCS, 
including the time the individual is exposed to reduced pressure, the degree of physical 
activity, the ambulation contact forces at reduced pressure, the pressure profile, repeated 
exposure to hypobaric pressures etc.9 To reduce the risk of DCS when transitioning from 
the cabin atmosphere to the EVA suit environment, crewmembers are exposed to 100% 
O2 for varying periods of time in an attempt to “washout” N2 from the body tissue. These 
procedures reduce but do not entirely eliminate N2 from the tissues, but do reduce the 
EVA crewmembers’ R-value at the time of decompression to the lower EVA suit 
pressure. The current shuttle and ISS EVA suit operates at a suit pressure of 4.3 psia for 
maximum mobility and reduction of crewmember fatigue. It is assumed that planetary 
EVA suits will operate at pressures near 4.3 psia. 
For the proposed habitat cabin atmospheric pressure of 8.0 psia (414.5 mmHg) at 32% 
ppO2, the ppN2 is 5.43 psia (281.9 mmHg). The R-value without additional in-suit 
prebreathe at a suit pressure of 4.3 psia is: 
 
      R =   5.43  = 1.23
 4.3 
 
  
The R-value, after a proposed maximum acceptable  60 minute in-suit 100% oxygen 
prebreathe, is calculated as: 
     R =   4.86  = 1.13
 4.3 
 
3.4.1 Reducing In-suit Prebreathe Time by Living in a Hypobaric and Mild Hypoxic 
Environment 
 
     At this time an acceptable R-value for exploration EVA’s has not been determined. 
That determination will be made as part of an integrated approach that would first define 
the acceptable decompression risk for different phases of the mission (The Exploration 
DCS Risk Definition and Contingency Plan). The prebreathe verification tests would be 
conducted using an EVA simulation that is appropriate with respect to metabolic rates, 
time, and ambulation contact forces. In general, for a given suit pressure, the amount of 
prebreathe time required for a given R-value will be reduced by reducing the nitrogen 
partial pressure in the habitat or lander. Prebreathe time could be completely eliminated if 
the habitat atmosphere was 100% O2. However, a balance must be achieved between the 
increased risk of fire at high O2 concentration and the decreased risk of DCS as N2 
pressure in the habitat is reduced. The concentration of O2 and therefore risk of fire for a 
given total pressure can be slightly reduced if mild hypoxia is accepted. The degree of 
hypoxia anticipated is equivalent to living in Denver Colorado, or Albuquerque New 
Mexico, at about 5,280-6000 feet altitude. 
     Even small reductions in the nitrogen partial pressure of the habitat can result in 
significant reduction in prebreathe time. To illustrate this point we compare the 
  
prebreathe times required to achieve different R-values from different CEV and habitat 
atmosphere options:  
 
I. 10.2 psia @ 26.5% O2 with a 60 minute in-suit prebreathe to achieve an R-value of 1.55 for 
contingency EVAs from the Crew Exploration Vehicle (CEV). This is a hypobaric and mildly 
reduced-oxygen environment, equivalent to breathing air at 3,500 feet altitude. To achieve the 
same R-value as the lower habitat pressures in option II and III would require 224 and 252 
minutes, respectively.  
 
II. 8.0 psia @ 32.0% O2 with a 60 minute in-suit prebreathe to achieve an R-value of 1.13 for 
lunar EVAs. This is a hypobaric and mildly reduced-oxygen environment, equivalent to breathing 
air at 5,000 feet altitude.   
 
III. 7.6 psia @ 32.0% O2 with a 60 minute in-suit prebreathe to achieve an R-value of 1.07 for 
Mars EVAs. This is a hypobaric and mildly reduced-oxygen environment, equivalent to breathing 
air at 6,500 feet altitude.   
 
Whereas the specific acceptable R-value for exploration EVAs has yet to be determined, 
it is clear that reduction in habitat nitrogen partial pressure will result in a significant 
reduction in prebreathe time. 
 
4.0 Conclusion 
 
The medical concerns of the integrated exploration operational atmosphere were 
taken into consideration in developing the EAWG recommendations, and 
exploration medical concurred that the current recommendations provide an 
  
appropriate blend of operational enhancement and DCS risk mitigation features, 
that justify the slight transient risks associated with mild hypoxia and acute 
mountain sickness. 
 
     Humans adapt to hypoxic exposure over a period of days to weeks (45-60 days) by 
increasing minute ventilation, splenic contraction, redistribution and increase in 
circulating blood volume, augmenting the oxygen carrying capacity of the blood.26,27,34 
The proposed mission transitions the vehicle atmospheric profile from a launch 
atmosphere of 14.7 psia and 21% O2 to a CEV atmosphere of 10.2 @ 26.5% O2 over a 
period of several days. The en route pressure will likely be reduced during lunar orbit in 
preparation for attainment of a surface cabin pressure of 8.0psia @ 32% O2. Planned 
lunar outpost habitat pressures may be as low as 7.6 mmHg, possibly with O2 
concentrations as high as 34%. The corresponding launch PAO2 (103 mmHg or 1.98 psia) 
to CEV (86 mmHg or 1.65 psia) and surface PAO2  (81 mmHg or 1.56 psia) represents an 
altitude equivalent of 3,500 ft to 5,000 ft., well within the acceptable physiological range.     
     However, any factor that could reduce crew health and performance should be 
minimized.  There is not an abundance of data specific to that required for the spaceflight 
AMS risk assessment.  There are only four reports about a PB effect per se on the risk of 
AMS induced by HH and six reports on the combined effects of HH and simulated μG 
adaptation that have some application here.  So all conclusions listed in this summary are 
based on extrapolation or interpolation from limited information.   
 
1.  Although initial signs and symptoms of AMS in susceptible subjects are expected after 
acutely but sustained exposure to between 1,981 m (6,500 ft at PAO2 = 75 mmHg) and 2,590 m 
  
(8,500 ft at PAO2 = 67 mmHg), it is likely that these would be self-limiting once acclimatization 
occurs.   
 
2.  At 8.0 psia (4,876 m or 16,000 ft) with a nominal PAO2 = 77 mmHg it is likely that 
susceptible astronauts simultaneously undergoing adaptation to μG will experience signs and 
symptoms of AMS.   
 
3.  No clinically significant increase in HCT or blood viscosity is expected as RBC mass, 
plasma, and total body water volumes adjust to the combined HH and μG environment.  A 
transient increase to a mean HCT of about 50%, possibly as high as 55% in a particular 
crewperson, would be predicted based on the data for the combined effects of HH and adaptation 
to μG as envisioned for the CEV program.  However, typical μG adapted spaceflight HCT values 
are in the low normal range, from 36-40% depending on gender. 
 
4.  The repeatedly validated operational experience with the Shuttle staged denitrogenation 
protocol at 10.2 psia (10,000 ft) while breathing 26.5% O2 (PAO2 = 85 mmHg) in μG-adapted 
astronauts suggests that a similar low risk of AMS can be expected for the proposed CEV 
environment.   
 
5.  On balance, there is no definitive evidence for an exaggerated (negatively synergistic) 
response to the combination of HH and adaptation to μG.  On the contrary, the limited evidence 
suggests that one stressor tends to counteract the other.         
 
  
4.1 Risk Mitigation Plan: 
 
     There is no single study that addresses the exact conditions for the proposed nominal 
Constellation vehicle environment:  adaptation to μG with a breathing environment at 8.0 psia 
(16,000 ft altitude) with 32% O2 - 68% N2, an acute PAO2 of about 77 mmHg.  Therefore, 
recommendations that follow are based on extrapolations and judgment from an exhaustive 
literature review, but from tests that are different from the proposed CEV, LSAM, and long-
duration surface habitat environments.   
 
1.  Due to the assumed lack of significant negative synergistic interaction between HH exposure 
with μG adaptation, expected for the proposed CEV environment.  The risk of AMS is 
anticipated to be low, and only in a small percentage of susceptible crewmembers. If AMS was 
to develop, any AMS signs and symptoms would be mild, and transient, therefore no special 
qualification standard is required. 
 
2.  Develop the rationale and procedures to easily increase ambient PB, if required,  
 
3. Use medications such as acetazolamide, dexamethasone, and supplemental O2 on a 
countermeasure (prophylactic) to reduce AMS risk or or as-needed to provide effective 
treatment if required.  Caution is warranted here for several reasons:  acetazolamide may 
be prescribed for diagnosed AMS when in fact signs and symptoms are from motion 
sickness. Acetazolamide can have side effects due to the additional diuretic effects or 
altered taste sensation. Also, the inverse- medication for motion sickness may be 
incorrectly prescribed for AMS.  AMS and motion sickness share many of the same signs 
  
and symptoms, and may appear along similar time course.  Often sleep medication is 
prescribed due to the many distractions in a small space vehicle.  However, sleep 
medications are contraindicated if AMS is suspected.  A sleep medication would likely 
worsen signs and symptoms of AMS.      
 
3.  Consider pre-flight testing to identify astronauts that are not resistant to (i.e. tolerant of) the 
atmospheric changes in the CEV environment, and provide special training and risk mitigation 
plans for those identified as susceptible, versus reassignment to a different mission. 
 
4.  Pre-adapt crews to a hypoxic environment prior to launch to blunt any combined negative 
effects of HH exposure with μG adaptation shortly after launch.  
 
5.  Develop an acclimatization plan through the gradual reduction in PAO2 during the initial 
phase of the missions, which should significantly reduce the likelihood of AMS signs and 
symptoms. 
 
6.  Consider inclusion of a plan to breathe 100% O2 by mask over several intervals of time 
during the acclimatization to the μG plus HH exposure.  Breathing 100% O2 is shown to blunt 
the negative physiological effects of subsequent HH exposure.  
 
       
  
4.2 Recommendations 
 
     We have provided an evidence-based approach for selecting the optimal total 
pressure-oxygen concentration levels for future spacecraft and habitats. Careful 
consideration of the current evidence reveal crewmembers will have minimal detrimental 
physiological effects of mildly reduced oxygen partial pressure equivalent to 3,500 ft to 
5,000 feet above Earth sea level. Mission efficiency can be significantly improved under 
these atmospheric parameters by reducing or eliminating the dedicated oxygen prebreathe 
by the EVA crew. Depending on the hypobaric and mild hypoxic conditions, there is a 
two to eight-fold reduction in the in-suit prebreathe time to achieve the stated R-values.  
     These recommendations are consistent with existing NASA Shuttle and ISS standards 
and flight rules for breathable atmosphere and oxygen concentration, so that the CEV and 
habitat can be designed with no new materials limitations. The short term CEV to ISS 
and lunar transit missions will stay within the known operational experience base and 
should not require any new Earth-based physiological testing for the combined effects of 
microgravity and hypoxia. However, the proposed lander and habitat recommendations 
will require that the current NASA Standard 3000 (HSIS) total pressure and oxygen 
concentration limits be amended to accommodate the new environmental atmosphere 
ranges. These recommendations will also require materials ignition and flammability 
testing and certification to 34% oxygen concentration. Data collected during lunar 
missions (with increasing duration) will be used to formulate the plan for Mars 
exploration, with the assumption that the physiological interactions of reduced gravity 
and lower oxygen tension will be diminished as the gravity level increases on the Martian 
surface relative to the Moon. Implementing these recommendations, in addition to 
  
bringing some new challenges, will provide significant improvements in operational 
productivity for planetary surface exploration. 
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